Featured
Last news
Vogenx Announces Closing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $13.00 per share. All of the shares were offered by Vogenx. The gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $81.3 million.
Humanoid Judge Tries Simulated Case
Sophia the Robot presides over a mock courtroom case during the 2026 Burton Awards, exploring the intersection of artificial intelligence, law, and legal innovation.
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET
Newsmax Announces Second Quarter 2026 Financial Results
Company Reports Record Quarterly Revenues of $54.1 million, a 16.5% Year-Over-Year IncreaseBroadcast Revenues Increase to $45.8 million, a 20.5% Increase Year-Over-YearCompany Reports Net Income of $2.9 million and Adjusted EBITDA of $5.7 million, Its First Profitable Quarter as a Public Company
Tenon Medical Reports Second Quarter 2026 Financial Results
~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~~ Received FDA 510(k) Clearance for Updated Catamaran® SI Joint Fusion System ~~ Physician and Distributor Training Events Increased 98% in 1H 2026 Compared to 2H 2025, Supporting Record Monthly Case Volume in July 2026 ~~ Closed $4.2 Million Public Offering Subsequent to Quarter End ~
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026.
NextBoat Inc. Announces Fiscal Second Quarter 2026 Results
Second quarter 2026 revenue increased 88.4% year-over-year to a record $59.1 millionRecord number of units transacted, 138% year-over-year increase
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company has issued new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire on the five-year anniversary of the date of such stockholder approval. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-288061), Form S-1MEF (File No. 333-288134), Form S-3 (File No. 333-284969) and Form S-3 (File No. 333-283983).
Dr. Louis DeJoseph Outlines Important Considerations for Neck Lift Candidates
Dr. Louis DeJoseph reviews who may benefit from a neck lift and why surgeon credentials, aesthetic style, and realistic expectations matter when considering treatment.
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026Near-Term Regulatory CatalystFormal review underway: Ukraine's Ministry of Health accepted the Entolimod dossier for formal review on July 22, 2026.Technical assessment underway: Ukraine's Ministry of Health has begun technical assessment of the dossier and issued its first round of questions, relating to the physicochemical characterization of the drug product that would be supplied under a potential stockpiling arrangement.Defined pathway: The Company has identified the analytical testing, quality-control validation, GMP verification, import-documentation, and Ukrainian-language labeling requirements applicable to the registration process.Potential Q4 decision: Valion Bio believes a regulatory decision could occur as early as the fourth quarter of 2026; there can be no assurance regarding timing or outcome.First potential national registration: A favorable decision would represent Entolimod's first national registration.Potential government-market pathway: Registration could establish a pathway toward possible inclusion in Ukraine's national strategic reserves and future government procurement. No procurement, purchase, or stockpiling agreement has been executed.
MDCE Highlights StrainScan Pro for Multi-Billion-Dollar Cannabis Dispensary Sector with Enterprise iPad Air Solution (OTC Pink:MDCE)
Proprietary AI Vision Platform Delivers Rapid Strain Identification and Quality Verification Tools for Licensed Multi-Location Dispensary Operators
BODYWELLE Brings Professional Football-Level Recovery to Miami Beach With EMSculpt NEO
The Miami Beach practice offers the same EMSculpt NEO platform recently added to a professional football team's recovery program, including its functional health and rehabilitation protocols.
New to The Street Signs 12-Part Media Series with SafeSpace Global (SSGC)
Integrated national campaign to feature long-form executive interviews, earned media, television commercials, outdoor billboards and accredited investor events
RenX Enterprises Corp. Reports Second Quarter 2026 Results: Record Quarterly Revenue of $4.26 Million, Logistics Segment Profitable for Second Consecutive Quarter
Microtec UTM 1200 Turbo Mill in Transit to Myakka City for Second-Half 2026 Commissioning; Land Clearing Division Launched with First Purchase Order; Two Primary Operating Segments Delivering Sequential Revenue Growth
Lexaria Enters a Material Transfer Agreement With PegBio
KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.
Wi2Wi Announces Strategic Equipment Investments to Expand Production Capacity
Advanced Seam welding and Cleanroom Systems to Be Fully Operational in Q4 2026
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure.
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026.
374Water and Arcadis Team Receives U.S. Department of Defense Success Memo Opening Pathway for AirSCWO(TM) Technology for PFAS Destruction at Commercial Scale
The DoD Success Memo enables government contracting officers to rapidly procure goods and services across all Federal agencies, accelerating deployment of 374Water's AirSCWO technology into the large and growing Federal marketplace.
American Rebel Light Beer Rallies Patriotic Americans With "Historic Moments" With American Rebel Beer Video Campaign Encouraging Patriots to "Be a Rebel"
Historic Founders and American Rebel CEO Andy Ross Lead Patriotic Call-to-Action Inviting Americans to Stand Tall, Stand Proud and "Be A Rebel" as America Continues to Celebrate 250 Years of FreedomLong-Form Feature Debuts Following Independence Day Preview; Ongoing Short-Form Series to Spotlight Historic American Patriots Alongside American Rebel Holdings, Inc. (OTCID:AREB) CEO Andy Ross and American Rebel Light Beer
Military Health IT Enters Its Post-EHR Era as AI, Readiness and Battlefield Care Drive the Next Federal Technology Wave
Black Book's 13th annual Military/DOW Health Tech market report identifies the buyers, budgets and 2027-2028 opportunities shaping healthcare technology investment across the Defense Health Agency, Department of Defense, military services and Department of Veterans Affairs.
INEO to Present at Emerging Growth Conference on August 19, 2026
CEO Kyle Hall to present live online at 1:10 p.m. Eastern Time
Healthcare Machine Learning Hits Production Scale as Governance Falls Behind, Black Book's Fourth Annual Report Finds
U.S.-EU benchmark finds 78% of healthcare organizations operate AI/ML in sustained production, while only 19% maintain complete lifecycle controls
Who Does MTF Body Feminization Surgery?
MTF Body Feminization Surgery Is Done by Dr. Javad Sajan, Who Accepts Insurance for Body Feminization Surgery
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue in Canada
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 13
InterContinental Hotels Group PLC (the "Company")Purchase of own shares
Colombia enters 'final phase' of quake search as toll hits 265
Colombia's earthquake rescue efforts entered what officials called the "final phase" on Wednesday, as rescuers searched for signs of life beneath collapsed buildings before the critical first 72 hours came to an end.
Meta meets its own 'tobacco' moment as jury selection kicks off trial
Jury selection kicked off on Wednesday in a California courtroom where Instagram and Facebook owner Meta will defend itself against allegations of harming children in a new trial which experts describe as social media's big tobacco moment.
Rob Reiner son denies grand jury murder charges
The son of legendary US film director Rob Reiner denied new charges of killing both his parents when he appeared in court on Wednesday after grand jury indictments were unsealed.
Colombia quake rescue efforts enter 'final phase' as toll hits 239
Colombia on Wednesday declared three days of mourning for victims of an earthquake that killed 239 people, as rescuers entered what officials called the final phase of the search for survivors.
Tourists rush to Mount Etna as Italian volcano erupts
Spectacular images of lava flowing down the slopes of an erupting Mount Etna have drawn flocks of tourists to the Italian volcano -- to the worry of local guides.
Nigeria kidnap victims escape 'hellfire' captivity beaten, malnourished
Visibly frail and malnourished children and women lay on rows of hospital beds, their bodies bearing the scars of six months of captivity deep in the Nigerian bush.